Navigation Links
Genmab Announces 2007 First Half Year Results
Date:8/22/2007

Summary: Genmab Reports Results for the Six Month Period Ended June 30,

2007

COPENHAGEN, August 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the six month period ended June 30, 2007. During this period, Genmab reported the following results:

Genmab's revenues were DKK 279.6 million (approx. USD 50.7 million) for the first half of 2007. In the same period of 2006, Genmab recognized DKK 74.3 million (approx. USD 13.5 million) in revenues.

An Operating Loss of DKK 118.9 million (approx. USD 21.6 million). This compares to an Operating Loss of DKK 187.5 million (approx. USD 34.0 million) reported for the corresponding period of 2006.

Net Financial Income totaled DKK 31.8 million (approx. USD 5.8 million), compared to Net Financial Expenses of DKK 2.3 million (approx. USD 0.4 million) in the first six months of 2006. Net Financial Income has benefited from the higher average cash position, whereas the negative net financial income reported for the first half of 2006 was impacted by increasing interest rates and weakening of the USD against the DKK.

A Net Loss of DKK 87.0 million (approx. USD 15.8 million) compared to a Net Loss of DKK 189.8 million (approx. USD 34.4 million) for the same period in 2006. The Net Loss per share was DKK 2.01 (approx. USD 0.36) for the first half of 2007 compared to DKK 4.96 (approx. USD 0.90) in the first half of 2006.

Genmab ended the six month period with a cash position of DKK 3.980 billion (approx. USD 722 million), which is a net increase of DKK 2.256 million (approx. USD 409.4 million) from the end of 2006.

Highlights

During the second quarter of 2007, Genmab achieved a number of business and scientific milestones, as follows:

On June 29, Genmab regained all rights to HuMax-CD4(R) (zanolimumab) from Merck Serono S.A. and announced final data from the HuMax-CD4 Phase II data in cutaneous T-cell lymphoma (C
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ... Oral Amphotericin B (Oral Amp B) drug candidate ... ImmuneCarta®, the immune monitoring business unit of Caprion, ... Amp B in reactivating latent HIV viral reservoirs ... with antiretroviral therapy. Memory cells, ...
(Date:8/18/2014)... Tampa, FL (Aug. 18, 2014) -- A new ... South Florida (USF) Morsani College of Medicine and ... the life-threatening complications of interventional cardiovascular disease treatment. ... model that the novel molecular therapy could selectively ... healing following a medical procedure using a balloon ...
(Date:8/18/2014)... 2014   Sterne, Kessler, Goldstein & Fox P.L.L.C. ... Washington, DC , announced today that it has ... (IPR) with the U.S. Patent and Trademark Office (USPTO) ... Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions aim to ... Genetics, Inc. These patents have been asserted against GeneDx ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... Quarterly presents a 360-degree look at the "state of ... drugs. This CQ Forum will include a panel discussion ... regarding the complex structures of biologics products vs. traditional ... these products save money for consumers? What is the ...
... June 15 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal ... James M. Frincke Ph.D. as President and CEO of Hollis-Eden ... company,s board of directors. , , Dr. Frincke joined ...
... June 15 Nanopoint Inc., an award-winning developer ... announced that effective immediately its cellTRAY Imaging System ... European marketplace. Nanopoint,s cellTRAY Imaging and Fluidics Systems ... including drug discovery, assisted reproductive technology (ART), stem ...
Cached Biology Technology:Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 2Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO 3Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems 2
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
(Date:8/19/2014)... retail seafood counters in 10 different states show ... to unexpectedly high levels of mercury, a harmful ... fish of the same species, but from a ... according to new research by University of Hawai,i ... is essential to allow consumers to choose sustainable ...
(Date:8/19/2014)... identified a biomarker strongly associated with basal-like breast ... to many types of chemotherapy. The biomarker, a ... new therapeutics designed to treat this often deadly ... from The Cancer Genome Atlas, molecular biologists Curt ... computational and bioinformatics techniques to detect patterns of ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... and vegetables instead of cookies and soda pop. Consider ... applaud a lunchtime workout rather than criticizing the cut ... encourages walking the stairs instead of riding the elevator. ... by Community Health Councils, Inc. (CHC) in Los Angeles ...
... Cold Spring Harbor Laboratory on Long Island have identified which ... the chief target of the widely prescribed antidepressant Prozac. This ... for depression, with fewer side effects, to be developed. , ... the factors that control how, when, and where new neurons ...
... tumor and settles in a new location, where it ... assays for this process, which is known as metastasis, ... across the surface of a matrix, traveling in a ... approach misses some crucial phenomena. , Working in the ...
Cached Biology News:UCLA study of community health project shows how group dynamics affect fitness, eating habits 2UCLA study of community health project shows how group dynamics affect fitness, eating habits 3Prozac's target revealed 23-D model reveals secrets of metastasis 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
... processes up to 48 lanes, 24 bi-directional, ... can be from either slab gel or ... chemistries. The detection parameters in Explorer have ... consistency. We have built Explorer for ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: